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LETTERS TO THE EDITOR
Anemia and Poor
Prognosis in Advanced Heart Failure
I read with great interest the study by Horwich et al. (1) on the
association of anemia with poor prognosis in advanced heart
failure. The investigators observed that mortality decreased in
linear fashion as hemoglobin level increased without excess mor-
tality at the highest hemoglobin level. However, hemoglobin level
17 g/dl was seen in only 3% of men and 1% of women. Thus, the
small number of patients at high hemoglobin level could have
limited the investigators’ ability to observe a U-shaped relation-
ship.
The percentage of patients with chronic obstructive lung disease
who are the most likely candidates to have high hemoglobin were
not listed in the report. I would appreciate the investigators’
comments.
Jalal K. Ghali, MD
Cardiac Centers of Louisiana
2551 Greenwood Road, Suite 350
Shreveport, Louisiana 71103
E-mail: jkgalt@shreve.net
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REPLY
We appreciate Dr. Ghali’s interest in our recent investigation of
the relationship between hemoglobin (Hb) level and mortality in
patients with advanced heart failure (HF) (1). We fully agree with
Dr. Ghali that our ability to detect excess mortality in HF patients
with above-normal Hb levels is limited by the small number of
patients in this population. The issue of optimal Hb levels in HF
and the possibility of a U-shaped relationship with regard to
mortality is increasingly important, as interest grows in correcting
anemia in HF using erythropoietin or newer analogues.
Prospective epidemiological studies such as the Framingham
Heart Study have demonstrated a U-shaped relationship between
hematocrit and mortality due to cardiovascular disease (2). A
preliminary analysis of elderly patients with mild to moderate HF
enrolled in the Evaluation of Losartan In The Elderly (ELITE) II
study showed a U-shaped relationship, with higher mortality seen
in men with hemoglobin levels 16.5 g/dl and in women with
hemoglobin levels 15.5 g/dl (3). It is interesting to note,
however, that an analysis of patients with mild to moderate HF in
the Studies Of Left Ventricular Dysfunction (SOLVD) database
failed to find a U-shaped relationship between hematocrit and
mortality in HF (4). Male patients with a hematocrit of 40% to
49% (n  4,235) had a mortality rate similar to those with
hematocrit levels above 50% (n  344).
As Dr. Ghali points out, the highest Hb level would be expected
in patients with severe chronic obstructive pulmonary disease
(COPD). Unfortunately, we do not have data on rates of COPD
in our cohort, as it was not a variable in our original study design.
In our study and the analysis of the SOLVD database, only a small
proportion of patients with HF had elevated hemoglobin or
hematocrit levels. Analyses of HF populations that include pa-
tients with increased Hb levels secondary to COPD, congenital
heart disease, or polycythemia vera would make assigning relative
mortality risk of elevated Hb versus the primary disease process
leading to increased hemoglobin extremely difficult.
Initial reports on using erythropoietin in mild to moderately
anemic HF patients in order to raise Hb to at least 12.5 g/dl have
shown clinical benefit and no adverse effects (5). Conversely, a
randomized controlled trial in 1,233 patients with HF or ischemic
heart disease along with renal failure on hemodialysis showed a
trend for increased cardiovascular events in subjects randomized to
maintain a hemoglobin of 14 g/dl compared to those with a goal
of 10 g/dl (6). Further clinical trials are needed to definitively assess
whether raising hemoglobin is beneficial in HF and whether there is
an upper limit of hemoglobin level above which benefit is lost.
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Los Angeles, California 90095
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Use of Term
“Non-Q Infarction” is Questioned
The recent study in JACC titled “Revisiting the Culprit Lesion in
Non–Q-Wave Myocardial Infarction” warrants comment (1). The
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term “non-Q infarction,” so common in today’s literature, repre-
sents sloppy thinking and sloppy science. Infarcts due to circumflex
disease may be very large and occasionally fatal and almost never
cause Q-waves. Significant anterior wall infarction often reduces
R-wave amplitude without resulting in Q-waves. The statement
that non–Q-wave infarcts are different from those with Q-waves is
using terminology that misrepresents the pathology. The view-
point article by Phibbs and colleagues (2), reviewing this issue in
detail three years ago in JACC, should be required reading. The
editorial staff can discourage the use of this term by insisting that
researchers who are ignorant of the pathology of infarction read
the article by Phibbs et al.
Myrvin H. Ellestad, MD
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REPLY
Dr. Ellestad assails our recent publication (1) on the angiographic
findings that characterize the “culprit lesion” in patients with acute
non–Q-wave myocardial infarction (MI) as representing “sloppy
thinking and sloppy science.” We presume this contentious alle-
gation is directed toward our use of the term “non–Q-wave MI,”
which, along with the comparator term “Q-wave MI,” is abhorred
by Dr. Ellestad and others (2) who contend that this binary
classification system “misrepresents the pathology” of MI and has
been termed variably as “a halfway house of the intellect” (3), as
having “no basis in scientific fact” (3), and as being “a meaningless
distinction” (2). Such pemicious rhetoric serves only to discredit
the stature and integrity of the physician assailants and to reinforce
the belief that such strong contrarian views are discordant with
mainstream cardiology opinion and practice.
At the time that the VANQWISH trial was conducted (1993 to
1996) and reported (1998) (4), the accepted terminology promul-
gated by both major national cardiology organizations (American
College of Cardiology and American Heart Association) consis-
tently endorsed the terms “Q-wave” and “non–Q-wave” MI in
their Consensus Management Guidelines (5), suggesting that
subject-matter experts and opinion leaders in cardiology did not
consider such concepts and terms meaningless or irrelevant.
More recently, of course, the older nomenclature of “Q-wave”
and “non–Q-wave” MI has been replaced by a new binary
classification system (“ST-segment elevation” and “non–ST-
segment elevation” MI), but because our current study was
undertaken in an era when the former classification was both
widely accepted and used, we decided for the sake of consistency to
use the term “non–Q-wave” MI rather than “non–ST-segment
elevation” MI in reference to our recent coronary angiographic
substudy (1).
We lament Dr. Ellestad’s uncritical assertion that both the
JACC editorial staff and the VANQWISH investigators are
“ignorant of the pathology of infarction.” We are all well aware of
the important distinction by which total or subtotal occlusion of
the circumflex or obtuse marginal branch coronary circulation can
“masquerade” as “non–Q-wave” MI; in fact, we were the first to
document (in 1987) the early electrographic findings of true
posterior MI (6), based on our careful and comprehensive assess-
ment of serial electrocardiograms (ECGs) in the Diltiazem Rein-
farction Trial (7). Moreover, we have contributed significantly to
the cardiology literature regarding the important electrocardio-
graphic features of non–Q-wave (non–ST-segment elevation) MI,
(8–10) and obviously incorporated these same rigorous criteria for
use in the VANQWISH study (4), which, we believe, permitted us
to accurately and reliably exclude posterior MI from our study
population.
Although our views are unlikely to dissuade Dr. Ellestad and
the vocal minority of cardiologists who tenaciously adhere to the
holistic notion that “an infarct is an infarct” electrocardiographi-
cally, pathogenetically, clinically, angiographically, and prognosti-
cally—a view, unfortunately, that ignores and disdains an abun-
dance of scientific information that has been acquired and
assimilated over more than 25 years of careful study—we hope that
our recent report on the angiographic characteristics of “culprit
lesions” will aid more cognitive cardiologists to focus on ways of
optimizing the care and management of their patients with
non–Q-wave/non–ST-segment elevation MI rather than getting
“lost among the forest and trees” of a largely outmoded terminol-
ogy battle that is of little relevance to contemporary clinical
practice.
William E. Boden, MD, FACC
Program Director
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